MCID: ACN001
MIFTS: 48

Acinar Cell Carcinoma malady

Categories: Rare diseases, Cancer diseases

Aliases & Classifications for Acinar Cell Carcinoma

Aliases & Descriptions for Acinar Cell Carcinoma:

Name: Acinar Cell Carcinoma 12 14 69
Acinic Cell Carcinoma 12 50
Carcinoma, Acinar Cell 42
Carcinoma Acinar Cell 52
Acinic Cell Tumor 50
Acinar Cell Tumor 69

Classifications:



External Ids:

Disease Ontology 12 DOID:3025
MeSH 42 D018267
NCIt 47 C3768
SNOMED-CT 64 45410002
UMLS 69 C0206685

Summaries for Acinar Cell Carcinoma

Disease Ontology : 12 A carcinoma that has material basis in abnormally proliferating cells, derives from spindle cells and/or derives from giant cells.

MalaCards based summary : Acinar Cell Carcinoma, also known as acinic cell carcinoma, is related to acinar cell carcinoma of pancreas and pancreatic acinar cell adenocarcinoma. An important gene associated with Acinar Cell Carcinoma is CHGA (Chromogranin A), and among its related pathways/superpathways are Pathways in cancer and Wnt Signaling Pathway and Pluripotency. The drugs Fluorouracil and Gemcitabine have been mentioned in the context of this disorder. Affiliated tissues include pancreas, liver and skin, and related phenotypes are Increased shRNA abundance (Z-score > 2) and endocrine/exocrine gland

Related Diseases for Acinar Cell Carcinoma

Diseases related to Acinar Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 102)
id Related Disease Score Top Affiliating Genes
1 acinar cell carcinoma of pancreas 12.4
2 pancreatic acinar cell adenocarcinoma 11.0
3 pancreatitis 10.7
4 bronchogenic cyst 10.3 APC BRCA2
5 bronchiectasis oligospermia 10.3 APC BRCA2
6 lung clear cell-sugar-tumor 10.3 BRCA2 TP53
7 hypothalamic adipsic hypernatraemia syndrome 10.2 BRCA2 SMAD4
8 peritoneal benign neoplasm 10.2 CHGA STK11
9 dystonia 10.2 CHGA STK11
10 classic congenital mesoblastic nephroma 10.2 CHGA TP53
11 anal canal paget's disease 10.2 CHGA STK11
12 infantile thalamic degeneration 10.2 APC TP53
13 vipoma 10.2 AFP CHGA
14 perineural angioma 10.2 CHGA TP53
15 malignant granular cell myoblastoma 10.2 AFP CHGA
16 endometrial squamous cell carcinoma 10.2 APC TP53
17 panniculitis 10.2
18 breast pericanalicular fibroadenoma 10.2 BRCA2 TP53
19 acantholytic squamous cell skin carcinoma 10.2 IGF2 TP53
20 mitochondrial neurogastrointestinal encephalopathy disease 10.1 APC SMAD4 TP53
21 familial hypopituitarism 10.1 APC SMAD4 TP53
22 extrahepatic biliary papillomatosis 10.1 CHGA SERPINA1
23 adenocarcinoma 10.1
24 hidradenoma 10.1 APC BRCA2 TP53
25 benign shuddering attacks 10.1 CHGA SMAD4 TP53
26 uterine corpus serous adenocarcinoma 10.1 AFP BCL10 CHGA
27 larynx liposarcoma 10.1 BRCA2 STK11 TP53
28 glomerulosclerosis, focal segmental, 7 10.1 APC SMAD4 STK11
29 inclusion-cell disease 10.1 APC IGF2
30 macular degeneration, early-onset 10.1 APC CTNNB1
31 rete testis adenoma 10.1 AFP SERPINA1
32 pontine hemorrhage 10.1 AFP SERPINA1
33 progressive external ophthalmoplegia with mitochondrial dna deletions, autosomal dominant 3 10.1 BRCA2 STK11 TP53
34 glioma susceptibility 1 10.1 CHGA IGF2 TP53
35 blood group incompatibility 10.0 IGF2 TP53
36 growth retardation hydrocephaly lung hypoplasia 10.0 CHGA SERPINA1 TP53
37 breast ductal carcinoma 10.0 CTNNB1 TP53
38 dfnb1 10.0 APC CTNNB1
39 granulocytopenia 10.0 CHGA CTNNB1
40 villoglandular endometrial endometrioid adenocarcinoma 10.0 BRCA2 TP53
41 childhood teratocarcinoma of the testis 10.0 BRCA2 CHGA SMAD4 STK11
42 kidney disease 10.0 AFP TP53
43 proliferative glomerulonephritis 10.0 AFP CTNNB1
44 adult botryoid rhabdomyosarcoma 10.0 AFP CHGA SERPINA1
45 klinefelter's syndrome 10.0 AFP CHGA SERPINA1
46 testicular trophoblastic tumor 10.0 AFP CHGA SERPINA1
47 ideomotor apraxia 10.0 APC CTNNB1 TP53
48 gallbladder signet ring cell adenocarcinoma 10.0 CHGA CTNNB1 TP53
49 asperger syndrome 10.0 APC CTNNB1 TP53
50 trachea squamous cell carcinoma 10.0 BRCA2 CTNNB1 TP53

Graphical network of the top 20 diseases related to Acinar Cell Carcinoma:



Diseases related to Acinar Cell Carcinoma

Symptoms & Phenotypes for Acinar Cell Carcinoma

GenomeRNAi Phenotypes related to Acinar Cell Carcinoma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-107 9.88 SMAD4
2 Increased shRNA abundance (Z-score > 2) GR00366-A-11 9.88 CTNNB1 SMAD4
3 Increased shRNA abundance (Z-score > 2) GR00366-A-113 9.88 CTNNB1
4 Increased shRNA abundance (Z-score > 2) GR00366-A-115 9.88 IGF2
5 Increased shRNA abundance (Z-score > 2) GR00366-A-132 9.88 IGF2
6 Increased shRNA abundance (Z-score > 2) GR00366-A-133 9.88 APC
7 Increased shRNA abundance (Z-score > 2) GR00366-A-161 9.88 IGF2
8 Increased shRNA abundance (Z-score > 2) GR00366-A-168 9.88 IGF2
9 Increased shRNA abundance (Z-score > 2) GR00366-A-177 9.88 APC CTNNB1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-192 9.88 APC
11 Increased shRNA abundance (Z-score > 2) GR00366-A-197 9.88 CTNNB1
12 Increased shRNA abundance (Z-score > 2) GR00366-A-202 9.88 APC
13 Increased shRNA abundance (Z-score > 2) GR00366-A-21 9.88 SMAD4
14 Increased shRNA abundance (Z-score > 2) GR00366-A-25 9.88 SMAD4
15 Increased shRNA abundance (Z-score > 2) GR00366-A-29 9.88 APC
16 Increased shRNA abundance (Z-score > 2) GR00366-A-42 9.88 SMAD4
17 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.88 SMAD4
18 Increased shRNA abundance (Z-score > 2) GR00366-A-46 9.88 SMAD4
19 Increased shRNA abundance (Z-score > 2) GR00366-A-47 9.88 CTNNB1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-49 9.88 APC CTNNB1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-54 9.88 SMAD4
22 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.88 IGF2
23 Increased shRNA abundance (Z-score > 2) GR00366-A-67 9.88 CTNNB1 IGF2
24 Increased shRNA abundance (Z-score > 2) GR00366-A-73 9.88 SMAD4 CTNNB1
25 Increased shRNA abundance (Z-score > 2) GR00366-A-74 9.88 SMAD4 APC CTNNB1 IGF2
26 Increased shRNA abundance (Z-score > 2) GR00366-A-79 9.88 CTNNB1 IGF2
27 Increased shRNA abundance (Z-score > 2) GR00366-A-81 9.88 SMAD4
28 Decreased viability in esophageal squamous lineage GR00235-A 9.56 AFP APC BCL10 BRCA2 CHGA CTNNB1

MGI Mouse Phenotypes related to Acinar Cell Carcinoma:

44 (show all 19)
id Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.26 AFP APC BCL10 BRCA2 CHGA CTNNB1
2 behavior/neurological MP:0005386 10.19 AFP APC BRCA2 CTNNB1 IGF2 SMAD4
3 homeostasis/metabolism MP:0005376 10.19 AFP APC BRCA2 CHGA CTNNB1 IGF2
4 cellular MP:0005384 10.17 APC BCL10 BRCA2 CTNNB1 IGF2 SMAD4
5 embryo MP:0005380 10.14 BCL10 BRCA2 CTNNB1 IGF2 SMAD4 STK11
6 cardiovascular system MP:0005385 10.12 APC CHGA CTNNB1 IGF2 SMAD4 STK11
7 hematopoietic system MP:0005397 10.11 APC BCL10 BRCA2 CTNNB1 IGF2 SMAD4
8 digestive/alimentary MP:0005381 10.09 APC BRCA2 CTNNB1 IGF2 SMAD4 STK11
9 immune system MP:0005387 10.08 CTNNB1 IGF2 SMAD4 STK11 TP53 BRCA2
10 mortality/aging MP:0010768 10.07 AFP APC BCL10 BRCA2 CHGA CTNNB1
11 craniofacial MP:0005382 10.03 APC CTNNB1 IGF2 SMAD4 STK11 TP53
12 integument MP:0010771 10 CTNNB1 IGF2 SMAD4 STK11 TP53 APC
13 liver/biliary system MP:0005370 9.95 AFP APC CTNNB1 IGF2 SMAD4 STK11
14 limbs/digits/tail MP:0005371 9.91 APC BRCA2 CTNNB1 IGF2 SMAD4 TP53
15 muscle MP:0005369 9.8 APC CTNNB1 IGF2 SMAD4 STK11 TP53
16 neoplasm MP:0002006 9.8 AFP APC BRCA2 CTNNB1 SMAD4 STK11
17 nervous system MP:0003631 9.76 APC BCL10 BRCA2 CTNNB1 IGF2 SMAD4
18 renal/urinary system MP:0005367 9.5 APC CHGA CTNNB1 IGF2 SMAD4 STK11
19 reproductive system MP:0005389 9.32 AFP APC BRCA2 CHGA CTNNB1 IGF2

Drugs & Therapeutics for Acinar Cell Carcinoma

Drugs for Acinar Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 122)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fluorouracil Approved Phase 3,Phase 2,Phase 1 51-21-8 3385
2
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
3
Levoleucovorin Approved Phase 3,Phase 2,Phase 1 68538-85-2
4
Pancrelipase Approved Phase 3,Phase 2,Phase 1 53608-75-6
5
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
6
Capecitabine Approved, Investigational Phase 3,Phase 2 154361-50-9 60953
7
Doxepin Approved Phase 3 1668-19-5 667477 667468
8
Histamine Approved, Investigational Phase 3 75614-87-8, 51-45-6 774
9
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
10
leucovorin Approved, Nutraceutical Phase 3,Phase 2,Phase 1 58-05-9 54575, 6560146 143
11 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
12 Liver Extracts Phase 3,Phase 1
13 Antidotes Phase 3,Phase 2,Phase 1
14 Anti-Infective Agents Phase 3,Phase 2,Phase 1
15 Antimetabolites Phase 3,Phase 2,Phase 1
16 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
17 Antiviral Agents Phase 3,Phase 2,Phase 1
18 Calcium, Dietary Phase 3,Phase 2,Phase 1
19 Micronutrients Phase 3,Phase 2,Phase 1
20 pancreatin Phase 3,Phase 2,Phase 1
21 Protective Agents Phase 3,Phase 2,Phase 1
22 Trace Elements Phase 3,Phase 2,Phase 1
23 Vitamin B Complex Phase 3,Phase 2,Phase 1
24 Vitamins Phase 3,Phase 2,Phase 1
25 Adjuvants, Anesthesia Phase 3
26 Analgesics Phase 3
27 Analgesics, Opioid Phase 3
28 Anesthetics Phase 3
29 Anesthetics, General Phase 3
30 Anesthetics, Intravenous Phase 3
31 Central Nervous System Depressants Phase 3
32 Narcotics Phase 3
33 pancreatic polypeptide Phase 3
34 Peripheral Nervous System Agents Phase 3
35 Protein Kinase Inhibitors Phase 3,Phase 2,Phase 1
36 Neurotransmitter Agents Phase 3
37 Psychotropic Drugs Phase 3
38
Erlotinib Hydrochloride Phase 3,Phase 1 183319-69-9 176871
39 Antidepressive Agents Phase 3
40 Antidepressive Agents, Tricyclic Phase 3
41 Histamine Antagonists Phase 3
42
Histamine Phosphate Phase 3 51-74-1 65513
43 Cola Nutraceutical Phase 3
44 Folate Nutraceutical Phase 3,Phase 2,Phase 1
45 Vitamin B9 Nutraceutical Phase 3,Phase 2,Phase 1
46
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
47
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
48
Oxaliplatin Approved, Investigational Phase 2,Phase 1 61825-94-3 5310940 9887054 6857599, 9887054 43805
49
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
50
Paclitaxel Approved, Vet_approved Phase 2,Phase 1 33069-62-4 36314

Interventional clinical trials:

(show all 49)
id Name Status NCT ID Phase
1 Two Chemotherapy Regimens Compared With Observation in Treating Patients With Completely Resected Pancreatic Cancer Completed NCT00058201 Phase 3
2 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
3 Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery Recruiting NCT01013649 Phase 3
4 Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy Active, not recruiting NCT01156142 Phase 3
5 Bortezomib and Carboplatin in Treating Patients With Metastatic Pancreatic Cancer Completed NCT00416793 Phase 2
6 Gemcitabine in Treating Patients With Advanced Salivary Gland Cancer That Cannot Be Removed During Surgery Completed NCT00003744 Phase 2
7 Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy Completed NCT01658943 Phase 2
8 Sunitinib in Treating Patients With Metastatic Pancreatic Cancer That Progressed After First-Line Therapy With Gemcitabine Completed NCT00397787 Phase 2
9 Triapine as First-Line or Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Pancreas Completed NCT00085371 Phase 2
10 Paclitaxel and Bryostatin 1 in Treating Patients With Advanced Pancreatic Cancer Completed NCT00031694 Phase 2
11 Lapatinib in Treating Patients With Recurrent and/or Metastatic Adenoid Cystic Cancer or Other Salivary Gland Cancers Completed NCT00095563 Phase 2
12 Trastuzumab in Treating Patients With Advanced Salivary Gland Cancer Completed NCT00004163 Phase 2
13 Cisplatin or Carboplatin Combined With Gemcitabine in Treating Patients With Locally Advanced, Recurrent, or Metastatic Malignant Salivary Gland Tumor Completed NCT00079079 Phase 2
14 Metformin Plus Modified FOLFOX 6 in Metastatic Pancreatic Cancer Recruiting NCT01666730 Phase 2
15 Combination Chemotherapy Before and After Surgery in Treating Patients With Localized Pancreatic Cancer Recruiting NCT02047474 Phase 2
16 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
17 Carboplatin and Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Metastatic Pancreatic Cancer Active, not recruiting NCT01280058 Phase 2
18 Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors Active, not recruiting NCT00859937 Phase 2
19 Dasatinib and Gemcitabine Hydrochloride or Gemcitabine Hydrochloride Alone in Treating Patients With Pancreatic Cancer Previously Treated With Surgery Active, not recruiting NCT01234935 Phase 2
20 Selinexor, Gemcitabine Hydrochloride, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Metastatic Pancreatic Cancer Suspended NCT02178436 Phase 1, Phase 2
21 Mitomycin C and Ifosfamide in Treating Patients With Metastatic Pancreatic Cancer Terminated NCT00967291 Phase 2
22 Trastuzumab in Treating Patients With Metastatic or Recurrent Salivary Gland Cancer Terminated NCT00126607 Phase 2
23 Title XELOX FOR SALIVARY GLAND CANCERS Terminated NCT00101075 Phase 2
24 MRI Mapping in Planning Radiation Therapy to the Base of Skull and Brain in Patients With Nonmetastatic Head and Neck Cancer Unknown status NCT00984074 Phase 1
25 CPI-613 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer Completed NCT01839981 Phase 1
26 Sorafenib Tosylate and Everolimus in Treating Patients With Advanced Solid Tumors and Metastatic Pancreatic Cancer That Does Not Respond to Gemcitabine Hydrochloride Completed NCT00981162 Phase 1
27 Head & Neck Cancer Survivorship: Physical and Functional Status Completed NCT00751816 Phase 1
28 Ultrasound-Guided Photodynamic Therapy With Photofrin & Gemcitabine for Patients With Locally Advanced Pancreatic Cancer Recruiting NCT01770132 Phase 1
29 Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies Recruiting NCT01643499 Phase 1
30 ADH-1, Gemcitabine Hydrochloride and Cisplatin in Treating Patients With Metastatic Pancreatic or Biliary Tract Cancer That Cannot Be Removed By Surgery Recruiting NCT01825603 Phase 1
31 Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery Active, not recruiting NCT00669734 Phase 1
32 CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer Active, not recruiting NCT01835041 Phase 1
33 Chemoradiation and Radiosurgery Boost in Treating Patients With Locally Advance Pancreatic Cancer That May or May Not be Removed by Surgery Active, not recruiting NCT01739439 Phase 1
34 GDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer or Solid Tumors That Cannot Be Removed by Surgery Active, not recruiting NCT00878163 Phase 1
35 Alisertib and Gemcitabine Hydrochloride in Treating Patients With Solid Tumors or Pancreatic Cancer Active, not recruiting NCT01924260 Phase 1
36 Stereotactic Radiosurgery in Treating Patients With Locally Advanced or Recurrent Head and Neck Cancer Active, not recruiting NCT00851253 Phase 1
37 Sirolimus and Vismodegib in Treating Patients With Solid Tumors or Pancreatic Cancer That is Metastatic or Cannot Be Removed By Surgery Suspended NCT01537107 Phase 1
38 Dynamic Contrast Enhanced MRI in Patients With Advanced Breast or Pancreatic Cancer With Metastases to the Liver or Lung Withdrawn NCT01741597 Phase 1
39 Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer Unknown status NCT00499733
40 PET Scans in Patients With Head And Neck Cancer Who Are Undergoing 3-Dimensional Conformal Radiation Therapy And Intensity-Modulated Radiation Therapy Completed NCT00809016
41 Growth Factor Levels in the Blood of Patients Undergoing Radiation Therapy for Epithelial Cancer Completed NCT00897793
42 Using Traditional Acupuncture in the Management of Cancer Treatment Related Lymphoedema Completed NCT00828516
43 Family Quality of Life Among Families With a Member Who is a Cancer Patient Completed NCT00544336
44 Gabapentin and Risk of Pancreatic Cancer and Renal Cancer (GPRD) Completed NCT01138124
45 Cancer in Patients With Gabapentin (GPRD) Completed NCT01236053
46 Stereotactic Radiosurgery and Metformin Hydrochloride in Treating Patients With Borderline-Resectable or Locally-Advanced Pancreatic Cancer Recruiting NCT02153450 Early Phase 1
47 High Volume Washing of the Abdomen in Increasing Survival After Surgery in Patients With Pancreatic Cancer That Can Be Removed by Surgery Recruiting NCT02757859
48 Chemotherapy and Radiation Therapy Before Surgery Followed by Gemcitabine in Treating Patients With Pancreatic Cancer Active, not recruiting NCT01821612
49 Surgery for Pancreatic Tumors and Collection of Tumor Tissue for Study Terminated NCT00100321

Search NIH Clinical Center for Acinar Cell Carcinoma

Cochrane evidence based reviews: carcinoma, acinar cell

Genetic Tests for Acinar Cell Carcinoma

Anatomical Context for Acinar Cell Carcinoma

MalaCards organs/tissues related to Acinar Cell Carcinoma:

39
Pancreas, Liver, Skin, Colon, Brain, Ovary

Publications for Acinar Cell Carcinoma

Articles related to Acinar Cell Carcinoma:

(show top 50) (show all 216)
id Title Authors Year
1
A comparison study of pancreatic acinar cell carcinoma with ductal adenocarcinoma using computed tomography in Chinese patients. ( 27660464 )
2016
2
Cytological findings of an ectopic pancreas of the stomach obtained at endoscopic ultrasound-guided fine needle aspiration, differential diagnosis from acinar cell carcinoma: a case report. ( 26786071 )
2016
3
Pancreatic panniculitis in a patient with pancreatic-type acinar cell carcinoma of the liver - case report and review of literature. ( 26895632 )
2016
4
Novel patient-derived xenograft mouse model for pancreatic acinar cell carcinoma demonstrates single agent activity of oxaliplatin. ( 27165126 )
2016
5
Systematic Review and Case Series Report of Acinar Cell Carcinoma of the Pancreas. ( 27842335 )
2016
6
TP53 alterations in pancreatic acinar cell carcinoma: new insights into the molecular pathology of this rare cancer. ( 26586531 )
2016
7
Acinar cell carcinoma of the pancreas: a rare disease with different diagnostic and therapeutic implications than ductal adenocarcinoma. ( 27629876 )
2016
8
Pancreatic panniculitis as a paraneoplastic phenomenon of a pancreatic acinar cell carcinoma. ( 27112929 )
2016
9
Metastatic pancreatic acinar cell carcinoma in a younger male with marked AFP production: A potential pitfall on fine needle aspiration biopsy. ( 27634114 )
2016
10
Omental acinar cell carcinoma of pancreatic origin in a child: a clinicopathological rarity. ( 26694824 )
2016
11
Pancreatic Acinar Cell Carcinoma. ( 27403122 )
2016
12
KRAS Mutations in Canine and Feline Pancreatic Acinar Cell Carcinoma. ( 27290644 )
2016
13
Acinar cell carcinoma: a report of 19 cases with a brief review of the literature. ( 27352960 )
2016
14
Endoscopic ultrasound in the diagnosis of acinar cell carcinoma of the pancreas: contrast-enhanced endoscopic ultrasound, endoscopic ultrasound elastography, and pathological correlation. ( 27853750 )
2016
15
Cytological findings and BCL10 expression in pancreatic acinar cell carcinoma: A Case Report. ( 27860444 )
2016
16
Efficacy of Chemotherapy in Patients with Unresectable or Metastatic Pancreatic Acinar Cell Carcinoma: Potentially Improved Efficacy with Oxaliplatin-containing Regimen. ( 27857025 )
2016
17
Pancreatic-type Acinar Cell Carcinoma of the Stomach Included in Multiple Primary Carcinomas. ( 27272797 )
2016
18
Acinar Cell Carcinoma of the Pancreas: Overview of Clinicopathologic Features and Insights into the Molecular Pathology. ( 26137463 )
2015
19
Ring around the ROSE: pancreatic acinar cell carcinoma diagnosed on site by EUS-FNA. ( 25805480 )
2015
20
Long-term survival following pancreatectomy and s-1 chemotherapy for pancreatic acinar cell carcinoma with peritoneal dissemination: a case report and literature review. ( 25569665 )
2015
21
ACINAR CELL CARCINOMA OF PANCREAS IN A CHILD: A RADIOLOGICAL PERSPECTIVE. ( 27004357 )
2015
22
Pancreatic acinar cell carcinoma with bilateral ovarian metastases, panniculitis and polyarthritis treated with FOLFIRINOX chemotherapy regimen. A case report and review of the literature. ( 25959244 )
2015
23
Prolonged Survival in a Patient with a Pancreatic Acinar Cell Carcinoma. ( 26600777 )
2015
24
Multimodal approach and long-term survival in a patient with recurrent metastatic acinar cell carcinoma of the pancreas: A case report. ( 26456669 )
2015
25
Expression of Albumin mRNA in Primary Hepatic Neoplasms and Acinar Cell Carcinoma. ( 26171921 )
2015
26
Pancreas-specific activation of mTOR and loss of p53 induce tumors reminiscent of acinar cell carcinoma. ( 26683340 )
2015
27
Acinar Cell Carcinoma of the Pancreas: A Literature Review and Update. ( 26246707 )
2015
28
Whole exome sequencing reveals recurrent mutations in BRCA2 and FAT genes in acinar cell carcinomas of the pancreas. ( 25743105 )
2015
29
Clinical features and CT/MRI findings of pancreatic acinar cell carcinoma. ( 26628966 )
2015
30
E-cadherin-negative acinar cell carcinoma of the pancreas: report of a case showing a solid pseudopapillary growth pattern. ( 25600280 )
2015
31
AFP-producing acinar cell carcinoma treated by pancreaticoduodenectomy in a patient with a previous radical subtotal gastrectomy by gastric cancer. ( 26155245 )
2014
32
Acinar cell carcinoma of the pancreas with colon involvement. ( 24550989 )
2014
33
Report of a case of acinar cell carcinoma with its differential diagnosis on endoscopic ultrasound-guided fine-needle aspiration cytology. ( 25210238 )
2014
34
DNA mismatch repair abnormalities in acinar cell carcinoma of the pancreas: frequency and clinical significance. ( 25058881 )
2014
35
APC alterations are frequently involved in the pathogenesis of acinar cell carcinoma of the pancreas, mainly through gene loss and promoter hypermethylation. ( 24590585 )
2014
36
Sudden disappearance of the blood flow in a case of pancreatic acinar cell carcinoma. ( 25400180 )
2014
37
FOLFIRINOX as first-line treatment for unresectable acinar cell carcinoma of the pancreas: a case report. ( 24526405 )
2014
38
Acinar cell carcinoma of exocrine pancreas in two horses. ( 24572625 )
2014
39
Clinics in diagnostic imaging (157). Acinar cell carcinoma (ACC) of the pancreatic tail. ( 25631965 )
2014
40
BCL10 as a useful marker for pancreatic acinar cell carcinoma, especially using endoscopic ultrasound cytology specimens. ( 23530562 )
2013
41
Comparison of pancreatic acinar cell carcinoma and adenocarcinoma using multidetector-row computed tomography. ( 24039366 )
2013
42
Use of panitumumab in the treatment of acinar cell carcinoma of the pancreas: A case report. ( 23426888 )
2013
43
A case report of a patient with advanced acinar cell carcinoma of the pancreas: long-term survival with regional, systemic and targeted therapy. ( 23748831 )
2013
44
The CT findings of pancreatic acinar cell carcinoma in five cases. ( 23465983 )
2013
45
Clinical and CT imaging features of pancreatic acinar cell carcinoma. ( 23358813 )
2013
46
Computed tomography features of acinar cell carcinoma of the pancreas. ( 22961504 )
2013
47
CT imaging features of acinar cell carcinoma and its hepatic metastases. ( 23232580 )
2013
48
Pancreatic panniculitis secondary to acinar cell carcinoma of the pancreas. ( 23763078 )
2013
49
Acinar cell carcinoma presenting as a duodenal mass: review of the literature and a case report. ( 23550393 )
2013
50
Primary acinar cell carcinoma of the liver. ( 23440644 )
2013

Variations for Acinar Cell Carcinoma

Copy number variations for Acinar Cell Carcinoma from CNVD:

7
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 107120 19 1205798 1228434 Amplification LKB1 Acinar cell carcinoma
2 118120 17 7571720 7590868 Mutation TP53 Acinar cell carcinoma

Expression for Acinar Cell Carcinoma

Search GEO for disease gene expression data for Acinar Cell Carcinoma.

Pathways for Acinar Cell Carcinoma

Pathways related to Acinar Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 18)
id Super pathways Score Top Affiliating Genes
1 12.36 APC BRCA2 CTNNB1 SMAD4 TP53
2
Show member pathways
12.32 APC CTNNB1 SMAD4 TP53
3 12.2 APC CTNNB1 SMAD4 TP53
4
Show member pathways
12.13 APC CTNNB1 SMAD4 TP53
5 12.02 AFP APC CTNNB1 SMAD4
6 11.92 APC CTNNB1 SMAD4 TP53
7
Show member pathways
11.88 BRCA2 SMAD4 TP53
8 11.87 APC CTNNB1 SMAD4
9 11.82 AFP APC TP53
10 11.81 AFP APC CTNNB1 SMAD4
11 11.52 APC CTNNB1 SMAD4 TP53
12 11.48 CTNNB1 SMAD4 TP53
13 11.3 APC CTNNB1 IGF2 TP53
14 11.23 SMAD4 STK11 TP53
15 11.21 BRCA2 CTNNB1 SMAD4 STK11 TP53
16 10.95 APC CTNNB1
17 10.91 APC CTNNB1 SMAD4
18 10.79 APC CTNNB1

GO Terms for Acinar Cell Carcinoma

Cellular components related to Acinar Cell Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 centrosome GO:0005813 9.56 APC BRCA2 CTNNB1 SMAD4
2 Wnt signalosome GO:1990909 9.16 APC CTNNB1
3 beta-catenin destruction complex GO:0030877 8.96 APC CTNNB1
4 catenin complex GO:0016342 8.62 APC CTNNB1

Biological processes related to Acinar Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 17)
id Name GO ID Score Top Affiliating Genes
1 cellular response to DNA damage stimulus GO:0006974 9.85 APC BRCA2 STK11 TP53
2 cell proliferation GO:0008283 9.73 BRCA2 CTNNB1 SMAD4 TP53
3 cell cycle arrest GO:0007050 9.67 APC STK11 TP53
4 positive regulation of apoptotic process GO:0043065 9.62 APC BCL10 CTNNB1 TP53
5 negative regulation of cell growth GO:0030308 9.58 SMAD4 STK11 TP53
6 positive regulation of transforming growth factor beta receptor signaling pathway GO:0030511 9.57 SMAD4 STK11
7 female gonad development GO:0008585 9.56 BRCA2 SMAD4
8 beta-catenin destruction complex disassembly GO:1904886 9.54 APC CTNNB1
9 response to X-ray GO:0010165 9.52 BRCA2 TP53
10 vasculature development GO:0001944 9.51 CTNNB1 STK11
11 gastrulation with mouth forming second GO:0001702 9.48 CTNNB1 SMAD4
12 positive regulation of histone H3-K4 methylation GO:0051571 9.46 CTNNB1 SMAD4
13 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.43 IGF2 STK11 TP53
14 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.37 BRCA2 TP53
15 positive regulation of transcription, DNA-templated GO:0045893 9.35 BCL10 BRCA2 CTNNB1 SMAD4 TP53
16 canonical Wnt signaling pathway GO:0060070 9.33 APC CTNNB1 STK11
17 negative regulation of cell proliferation GO:0008285 9.02 APC CTNNB1 SMAD4 STK11 TP53

Molecular functions related to Acinar Cell Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.65 APC BCL10 SERPINA1 SMAD4 TP53
2 protein kinase binding GO:0019901 9.62 APC BCL10 CTNNB1 TP53
3 disordered domain specific binding GO:0097718 9.37 CTNNB1 TP53
4 I-SMAD binding GO:0070411 9.16 CTNNB1 SMAD4
5 RNA polymerase II transcription factor binding GO:0001085 9.13 CTNNB1 SMAD4 TP53
6 protease binding GO:0002020 8.92 BCL10 BRCA2 SERPINA1 TP53

Sources for Acinar Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....